Ayala Pharmaceuticals, an Israeli clinical-stage company that develops medicines for cancers that are genetically defined, announced Tuesday it had closed a $30 million Series B funding round. The financing round was led by Swiss multinational pharmaceutical company Novartis, with participation from SBI JI Innovation Fund and existing investors Israel Biotech Fund, aMoon and Harel Insurance […]